Idexx Laboratories Stock Intrinsic Value – IDEXX Laboratories Stock Inches Up 0.21% on Positive Trading Day
June 17, 2023
☀️Trending News
On Friday, IDEXX ($NASDAQ:IDXX) Laboratories Inc. was one of the few stocks that made positive gains in the stock market. The stock price rose 0.21% to $470.83, reflecting the overall trend of the day. IDEXX Laboratories is a global leader in veterinary diagnostics and software solutions for animal health. In addition to its core business, the company also offers a range of other services, such as pet nutrition products and water testing services for humans. With strong financials and a broad footprint across the global veterinary diagnostics market, IDEXX Laboratories has continued to grow and evolve over the years.
Analysis – Idexx Laboratories Stock Intrinsic Value
GoodWhale is here to help you analyze the fundamentals of IDEXX LABORATORIES. We have used our proprietary Valuation Line to calculate the intrinsic value of the IDEXX LABORATORIES share at $541.1. This means that the stock is currently trading at $465.3, which is a fair price undervalued by 14.0%. This presents an opportunity to buy the stock at a discounted rate, while still receiving the intrinsic value of the stock. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Idexx Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 3.43k | 699.18 | 20.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Idexx Laboratories. More…
| Operations | Investing | Financing |
| 612.19 | -193.02 | -503.54 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Idexx Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.81k | 1.97k | 7.34 |
Key Ratios Snapshot
Some of the financial key ratios for Idexx Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.8% | 18.2% | 27.2% |
| FCF Margin | ROE | ROA |
| 13.3% | 95.7% | 20.7% |
Peers
The company’s main competitors are NeoGenomics Inc, SQI Diagnostics Inc, and Genetic Technologies Ltd. All three companies offer similar products and services, but IDEXX Laboratories Inc has the largest market share.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics is a cancer-focused company that provides testing and services related to the diagnosis and treatment of cancer. The company has a market cap of 956.68M as of 2022 and a Return on Equity of -3.79%. NeoGenomics offers a variety of services including genetic testing, molecular testing, and immunohistochemistry. The company also provides consultative services to oncologists and pathologists.
– SQI Diagnostics Inc ($TSXV:SQD)
SQI Diagnostics Inc. is a global provider of multiplexing diagnostic solutions. The company offers a range of products and services that are used in the early detection, diagnosis, and prognosis of disease. Its products are used in a variety of settings, including hospitals, clinics, and research laboratories. SQI Diagnostics Inc. has a market cap of 61.01M as of 2022. The company’s Return on Equity is -1578.51%. SQI Diagnostics Inc. is a global provider of multiplexing diagnostic solutions. The company offers a range of products and services that are used in the early detection, diagnosis, and prognosis of disease.
– Genetic Technologies Ltd ($ASX:GTG)
As of 2022, Genetic Technologies Ltd has a market cap of 27.7M and a Return on Equity of -23.54%. The company is involved in the development and commercialization of genetic testing products and services. Its products are used for the early detection of cancer and other diseases.
Summary
IDEXX Laboratories Inc. (IDXX) saw its stock price close slightly higher on Friday, increasing 0.21% to $470.83. This was a positive outlook on the company, as the stock market overall performed well. Investors should take this as a sign of continued growth and potential in the company, and should continue to monitor the stock for further developments.
